5 Firms Shape Amgen's $13.4B Celgene Drug Buy

Law360 (August 26, 2019, 7:36 AM EDT) -- Amgen will shell out $13.4 billion in cash to snap up Celgene's psoriasis and psoriatic arthritis drug, a deal shaped by five law firms that is aimed at lessening competition concerns with Bristol-Myers Squibb's Celgene takeover. 

The deal will see Amgen, led by Sullivan & Cromwell LLP, buy the global rights to Otezla as Bristol-Myers Squibb Co., advised by Kirkland & Ellis LLP and Arnold & Porter Kaye Scholer LLP, tries to ease the U.S. Federal Trade Commission's concerns with its $74 billion takeover of Celgene Corp., guided by Wachtell Lipton Rosen & Katz and Baker Botts LLP.

Otezla is currently...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.

  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!


Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!